WEKO3
アイテム
Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy
https://repo.qst.go.jp/records/66329
https://repo.qst.go.jp/records/6632913d78f84-f2a5-4566-8efd-b7209ee298a7
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-05-23 | |||||
| タイトル | ||||||
| タイトル | Prognostic Factors in High-Risk Prostate Cancer after Carbon-Ion Radiotherapy Combined with Long-Term Androgen Deprivation Therapy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kasuya, Goro
× Kasuya, Goro× Ishikawa, Hitoshi× Tsuji, Hiroshi× Makishima, Hirokazu× Nomiya, Takuma× Kamada, Tadashi× 粕谷 吾朗× 石川 仁× 辻 比呂志× 牧島 弘和× 野宮 琢磨× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: To determine the prognostic factors for biochemical recurrence (BR) and mortality in patients with high-risk localized prostate cancer after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT). Methods and Materials: A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding T4 disease, 614 patients received CIRT combined with LTADT for high- or very-high-risk disease, according to the National Comprehensive Cancer Network (NCCN) classification system. Results: Median follow-up time was 78.7 months, and 5-year rates of BR-free, prostate cancer-specific survival, and overall survival were 90.4% (95% confidence interval [CI]: 87.6 - 92.7), 98.5% (95% CI: 97.2 - 99.2), and 94.7% (95% CI: 92.8 - 96.5), respectively. T3a/b disease, Gleason score (GS) 9-10, percentage of positive biopsy cores (PPCs) > 75%, and age > 75 years had a significant impact on BR. Moreover, patients with T3b disease, GS 9-10, and PPCs > 75% had significantly higher prostate cancer-specific mortality (p = 0.007, p = 0.009, and p = 0.015, respectively) and overall mortality (p = 0.035, p = 0.025, and p < 0.001, respectively), on multivariate analyses. Conclusions: Prognostic factors for BR and mortality were identified. Patients with T3b disease, GS 9-10, and PPCs > 75% should be considered to have very-high-risk disease requiring a new treatment strategy. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | the 56th Annual Conference of the Particle Therapy Co-operative Group (PTCOG56) | |||||
| 発表年月日 | ||||||
| 日付 | 2017-05-13 | |||||
| 日付タイプ | Issued | |||||
